NVAX Earnings & Financial Statements
Novavax, Inc.
$9.18
-$0.80(-8.02%)
59
Overall
60
Value
70
Tech
47
Quality
Market Cap
$1.51B
Volume
3.49M
52W Range
$6.20 - $13.39
Target Price
$13.90
NVAX earnings and financial statements: Novavax, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NVAX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.16M | $983.71M | $1.60B | $197.58M |
| Cost of revenue | $73.04M | $202.74M | $343.77M | $902.64M | - |
| Operating income | $550.64M | -$248.93M | -$566.51M | -$644.74M | -$1.69B |
| EBITDA | $492.33M | -$108.04M | -$487.39M | -$604.71M | -$1.68B |
| Net income | $440.30M | -$187.50M | -$545.06M | -$657.94M | -$1.74B |
| EPS (diluted) | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B |
| Total liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B |
| Shareholders’ equity | -$127.75M | -$623.84M | -$716.93M | -$634.08M | -$351.67M |
| Cash and equivalents | $240.63M | $530.23M | $568.50M | $1.34B | $1.52B |
| Long-term debt | $246.30M | $223.41M | $223.94M | $197.70M | $323.46M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$244.63M | -$87.26M | -$713.97M | -$415.94M | $322.95M |
| Capital expenditure | -$6.39M | $178.00M | -$58.81M | -$92.98M | -$54.50M |
| Free cash flow | -$251.02M | -$101.90M | -$772.77M | -$508.92M | $268.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVAX | $9.18 | -8.0% | 3.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |